Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
New research sits at the center of this dementia and brain health question.
Recent research and FDA approvals confirm that early intervention can meaningfully slow Alzheimer’s disease progression. The past few years have brought a significant shift in how we approach this disease—from a position where we could only manage symptoms to one where we can actually delay cognitive decline, particularly when treatment begins in the earliest stages of the disease.
A 60-year-old woman diagnosed with mild cognitive impairment through a blood test in 2024 could now start lecanemab treatment and potentially gain six additional months before experiencing further cognitive decline, compared to her counterpart who remains untreated. This transformation is powered by three converging developments: newly approved medications that target the biological root causes of Alzheimer’s, a breakthrough blood test that can identify the disease before symptoms become severe, and emerging experimental treatments showing promise in early-stage disease. The window for intervention is narrower than many people realize—these treatments work best when cognitive decline is still minimal—but that window is now detectable and actionable in ways it never was before.
Table of Contents
- Can FDA-Approved Medications Slow Alzheimer’s Progression?
- Blood Tests Now Detect Alzheimer’s Before Symptoms Progress Far
- Experimental Treatments Show Early Promise in Halting Disease
- Weighing Treatment Benefits Against Real Medical Risks
- Lifestyle Interventions Remain Powerful and Underutilized
- The Critical Importance of Diagnosis Timing
- The Evolving Landscape of Alzheimer’s Care
- Conclusion
Can FDA-Approved Medications Slow Alzheimer’s Progression?
Two disease-modifying medications have now received FDA approval for early Alzheimer’s disease, and both demonstrate meaningful but modest slowing of cognitive decline. Lecanemab, approved in January 2023 and marketed as Leqembi, showed a 27% reduction in cognitive decline in clinical trials, translating to approximately a six-month delay in disease progression. Donanemab, approved more recently in July 2024, performed somewhat better, showing a 35% decrease in cognitive decline and a 4.36-month delay in progression. While these numbers may seem small on the surface, they represent the first time medicine has been able to address the underlying amyloid buildup in the brain rather than simply treating symptoms like memory loss.
Both medications work by clearing amyloid-beta plaques from the brain—the toxic protein accumulation now understood to be central to Alzheimer’s development. For context, a person with early-stage Alzheimer’s might experience noticeable cognitive decline over two years. Lecanemab could stretch that timeline to approximately two and a half years. Donanemab offers slightly more protection. These gains are modest but meaningful to families facing this disease, offering additional time with preserved cognitive function and reduced burden on caregivers during the early years.
Blood Tests Now Detect Alzheimer’s Before Symptoms Progress Far
For decades, Alzheimer’s could only be definitively diagnosed through expensive imaging tests or, in the past, only confirmed after death. In May 2025, the FDA approved the Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio test, marking the first blood-based diagnostic tool for Alzheimer’s disease in living patients. This is a watershed moment for early intervention because diagnosis drives treatment—without a clear diagnosis, doctors had no clear reason to start aggressive treatment in patients with only mild symptoms.
The test’s accuracy is impressive: clinical studies showed 91.7% accuracy when results were compared against PET imaging (the imaging gold standard) and 97.3% negative predictive value, meaning when the test comes back negative, patients can be reassured. This means a primary care doctor can now order a simple blood test, identify amyloid pathology before significant cognitive symptoms appear, and refer patients to treatment. A 58-year-old noticing occasional forgetfulness can get a definitive biological answer within days rather than months of specialized visits and imaging, potentially catching the disease at a stage where intervention is most effective.
Experimental Treatments Show Early Promise in Halting Disease
Beyond the approved medications, cutting-edge research is revealing new avenues for treatment. Northwestern University researchers recently identified a particularly toxic subtype of amyloid-beta and developed an experimental drug called NU-9 that dramatically reduced damage in mouse models of early Alzheimer’s disease—potentially stopping the disease before symptoms begin. While animal research doesn’t always translate to humans, these findings suggest the next generation of treatments may offer even greater protection than current options.
The significance of NU-9 and similar experimental approaches is that they’re being designed based on increasingly specific understanding of how Alzheimer’s develops at the molecular level. Rather than broad anti-amyloid approaches, researchers are targeting specific forms of the protein that appear to do the most damage. This precision approach mirrors how cancer treatment has evolved over recent decades—moving from one-size-fits-all chemotherapy to targeted interventions. However, these experimental drugs remain years away from human trials and approval, so people currently at risk cannot rely on them yet.
Weighing Treatment Benefits Against Real Medical Risks
Any discussion of lecanemab and donanemab must honestly address their most significant side effect: amyloid-related imaging abnormalities (ARIA). Research shows these medications carry 4.35 times higher risk of ARIA compared to control groups. ARIA can manifest as amyloid-related imaging abnormalities, microhemorrhages, or microinfarcts—essentially small bleeds or dead tissue areas in the brain that appear on imaging. Most people experiencing ARIA show no symptoms, but some develop headaches, vision changes, or confusion.
This means treatment isn’t a simple decision. A 70-year-old with early cognitive decline and multiple brain imaging abnormalities already present faces different risk-benefit calculations than a 62-year-old with clean imaging. The question doctors and patients must grapple with is whether a six-month delay in cognitive decline justifies a higher risk of asymptomatic brain microhemorrhages. Some patients will choose this tradeoff; others, particularly those with existing health conditions that increase stroke or bleeding risk, may reasonably decline treatment. This is why early, careful diagnosis combined with thorough patient education is essential.
Lifestyle Interventions Remain Powerful and Underutilized
While medications get the headlines, the largest long-term study of brain health in aging—the POINTER trial—confirmed that lifestyle interventions significantly slow cognitive decline in people at risk for Alzheimer’s. The study found that sustained physical activity, nutritious eating patterns, social engagement, and cardiovascular risk management improved cognition in older adults with Alzheimer’s risk factors. Unlike medications, these interventions carry no risk of side effects and offer broad health benefits.
This creates an important hierarchy: someone diagnosed with early Alzheimer’s ideally pursues both medication and lifestyle interventions, as the effects appear additive. However, lifestyle modifications work best when sustained, which is precisely what makes them challenging. A person committing to 150 minutes of weekly exercise, regular social activities, heart-healthy eating, and blood pressure management alongside medication stands to preserve cognitive function longer than someone choosing medication alone. Conversely, someone taking lecanemab but remaining sedentary, isolated, and eating poorly may gain less total benefit than the trial results suggest is possible.
The Critical Importance of Diagnosis Timing
The effectiveness of early intervention depends fundamentally on catching the disease before it progresses too far. The medications approved for Alzheimer’s work specifically for early cognitive decline—often called mild cognitive impairment or early-stage dementia. They have not been shown to benefit people who are asymptomatic but have amyloid plaques in their brains, nor do they work well in moderate to advanced dementia. This means the window for treatment is narrow and time-sensitive.
Access to blood tests like Lumipulse is therefore critical infrastructure. Not all primary care doctors currently offer this test, and not all insurance plans cover it yet. A person who waits two years before seeking evaluation, assuming memory changes are just normal aging, may miss the optimal window for intervention. Conversely, over-diagnosis of asymptomatic people with amyloid plaques raises questions about unnecessary treatment. Finding the right balance—identifying people with cognitive symptoms and amyloid pathology while not treating asymptomatic individuals—will likely become a major focus in clinical practice over the next few years.
The Evolving Landscape of Alzheimer’s Care
The pace of Alzheimer’s research is accelerating. The approvals of two disease-modifying medications in eighteen months, followed immediately by a blood-based diagnostic test, suggest we’re at an inflection point. Researchers are actively investigating whether earlier treatment—even in asymptomatic people with advanced amyloid pathology—could prevent cognitive decline entirely. Other drug candidates are in advanced trials, and combination therapies targeting multiple aspects of Alzheimer’s biology are being explored.
Looking forward, Alzheimer’s care is likely to shift toward a screening model similar to cardiovascular disease, where people receive blood tests and risk assessments years before symptoms appear. This could allow preventive treatment of truly at-risk individuals decades before they would develop memory problems. However, this future also raises important questions about who gets screened, who qualifies for treatment, and how to navigate the anxiety of knowing one has disease pathology without symptoms. The medical breakthroughs are now certain; the social and economic questions around implementation remain evolving.
Conclusion
The past three years have fundamentally changed the answer to whether we can slow Alzheimer’s. Yes, we now can—through medications that reduce cognitive decline by 27-35%, through blood tests that identify the disease with high accuracy before advanced symptoms appear, and through lifestyle interventions proven to support brain health. For a person recently diagnosed with early-stage Alzheimer’s, this represents hope that didn’t exist a decade ago.
However, these breakthroughs come with important caveats: medications work best in the narrow window of early cognitive decline, they carry real side effects that must be weighed carefully, and they’re most effective when combined with lifestyle changes. If you or someone you care about is experiencing cognitive changes, the next step is a conversation with your primary care doctor about screening. Early detection paired with evidence-based treatment offers the best chance of preserving cognitive function and maintaining quality of life for as long as possible.
You Might Also Like
- New Alzheimer’s Research Suggests Memory Loss May Be Preventable
- New Alzheimer’s Research Suggests Brain Aging May Be Reversible
- New Study Suggests Environmental Factors May Influence Alzheimer’s
For more, see Alzheimer’s Association — clinical trials.
